US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
2.880
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
November 03, 2021
- DehydraTECH-CBD also being evaluated in three other human clinical studies - Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Bioscience Corp. Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
↗
November 02, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1, designed to evaluate whether its DehydraTECH(TM)-CBD (“...
Via
Benzinga
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
November 01, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures
↗
November 01, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure...
Via
Benzinga
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
November 01, 2021
- New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
October 29, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
October 29, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp.'s DehydraTECH(TM) Addresses the Needs of Medical THC Users
↗
October 26, 2021
Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver...
Via
Benzinga
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
October 26, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
October 26, 2021
Via
CannabisNewsWire
New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping
October 22, 2021
Via
Investor Brand Network
Topics
Cannabis
Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
October 20, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
October 20, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
October 20, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
October 20, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry
October 19, 2021
Via
CannabisNewsWire
Topics
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry
October 19, 2021
Via
Investor Brand Network
Topics
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
October 13, 2021
Via
CannabisNewsWire
Topics
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
October 13, 2021
Via
Investor Brand Network
Topics
Cannabis
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 13, 2021
- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Cannabis
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
October 12, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
October 12, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Outcome of NIC-A21-1 Study Using DehydraTECH(TM)-Nicotine Pouches
October 08, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage
October 05, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
October 05, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
October 05, 2021
Via
CannabisNewsWire
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
October 05, 2021
- DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls - Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs
September 30, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats
September 29, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats
September 29, 2021
Via
CannabisNewsWire
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
